No quick cure for Amryt Pharma investors

Cathal Friel


IN A complete shift of gear, Cathal Friel has turned Fastnet Oil & Gas into Amryt Pharmaceuticals. At first sight, moving from a failing oil and gas business into a pharmaceutical operation specialising in ‘orphan’ drug development seems simply bizarre. Friel, who is both the... Read more »

To access this content, you must be a Phoenix subscriber.

Get access to The Phoenix online for only €2 per issue. This subscription allows our subscribers the option of far cheaper access to Goldhawk’s treasure trove.

Subscribe Now! I'm a Subscriber